Spectrum chemotherapy treatment patent ruled invalid by Federal Circuit

05-10-2015

Spectrum chemotherapy treatment patent ruled invalid by Federal Circuit

Tashatuvango / Shutterstock.com

The US Court of Appeals for the Federal Circuit has upheld a lower court’s ruling that Spectrum Pharmaceuticals’s Fusilev (levoleucovorin) patent is invalid and wasn’t infringed by generics company Sandoz.


Sandoz; US Court of Appeals for the Federal Circuit; patents; obviousness; Levoleucovorin; chemotherapy: ANDA; Novartis

LSIPR